TERN
NASDAQTerns Pharmaceuticals Inc.
Price$52.92-0.01 (-0.01%)
01:30 PM07:45 PM
News · 26 weeks67-40%
2025-11-022026-04-26
Mix3790d
- Other17(46%)
- Insider9(24%)
- SEC Filings9(24%)
- Analyst2(5%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by Terns Pharmaceuticals Inc.10-K/A - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECTerns Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- PRTerns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaFOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs. "There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies," said Scott Harris, chief development and operations officer at Terns. "This designation from the FDA su
- SECAmendment: SEC Form SC 14D9/A filed by Terns Pharmaceuticals Inc.SC 14D9/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Terns Pharmaceuticals Inc.SC TO-T/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- PRMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex
- PRMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. Following the purchase of shares in the tender offer, Terns will become a wholly owned subsidiary o
- SECSEC Form SC 14D9 filed by Terns Pharmaceuticals Inc.SC 14D9 - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-T filed by Terns Pharmaceuticals Inc.SC TO-T - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- INSIDERSEC Form 4 filed by Kuriakose Emil4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- PRTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted 23,316 restricted stock units (the "RSUs"), in the aggregate, of Terns common stock to the new e
- SECSEC Form S-8 filed by Terns Pharmaceuticals Inc.S-8 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form 10-K filed by Terns Pharmaceuticals Inc.10-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC14D9C filed by Terns Pharmaceuticals Inc.SC14D9C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- ANALYSTTerns Pharmaceuticals downgraded by H.C. WainwrightH.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral
- SECSEC Form SC14D9C filed by Terns Pharmaceuticals Inc.SC14D9C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECTerns Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximate
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash and represents an approximate premi
- INSIDERChief Executive Officer Burroughs Amy L. exercised 14,583 shares at a strike of $4.64 and sold $681,108 worth of shares (14,583 units at $46.71) (SEC Form 4)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- PRTerns Pharmaceuticals to Participate in Upcoming March Investor ConferencesFOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, March 9, 2026 at 1:40 p.m. ET Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: 1x1 MeetingsDate: Tuesday, March 10, 2026Location: Miami, FL The Citizens Li
TERN FAQ
7 questionsWhat does Terns Pharmaceuticals Inc. do?
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced...Where does TERN stock trade?
Terns Pharmaceuticals Inc. (TERN) is listed on NASDAQ.What sector and industry is TERN in?
Terns Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Terns Pharmaceuticals Inc. go public?
Terns Pharmaceuticals Inc. (TERN) completed its IPO in 2021.What are analysts saying about TERN?
Terns Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-03-25. Recent price targets range from $1500.00 to $2000.00.What companies are similar to TERN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare TERN side-by-side with any of them on Quantisnow.How can I track TERN on Quantisnow?
Quantisnow aggregates Terns Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TERN to receive live email and push alerts on every new disclosure.